T8057

Citronellyl acetate is a natural product

Evunzekibart is a human monoclonal antibody and a Fcγ receptor-dependent 4-1BB (CD137/TNFRSF9) agonist. Evunzekibart exerts potent antitumor immune activity by selectively activating effector T cells and NK cells in the tumor microenvironment. Evunzekibart is being investigated as a monotherapy or in combination with anti-PD-1/PD-L1 agents for the treatment of advanced solid tumors.

Dazukibart is a humanized IgG1κ anti-IFNB1 monoclonal antibody of murine origin, being investigated as a potential treatment for dermatomyositis, a complex autoimmune disorder pathologically characterized by the pronounced overexpression of interferon (IFN) inducible genes present within the blood, skin, and muscle tissue of affected patients.

Eurestobart is a humanized IgG1κ (IgG1 kappa) monoclonal antibody that specifically targets the enzyme ectonucleoside triphosphate diphosphohydrolase (ENTPDase).

Exlinkibart (LVGN-6051) is a humanised monoclonal antibody and agonist targeting CD137/TNFRSF9, inducing cytotoxic T lymphocyte (CTL) proliferation and promoting antitumour immune responses.

Firastotug, an IgG1κ antibody, targets CTLA4, a cytotoxic T lymphocyte-associated protein that serves as a crucial immune checkpoint in autoimmunity and cancer [1].

Becotatug (JMT101) is a humanised monoclonal antibody targeting EGFR, demonstrating antitumour activity when combined with Osimertinib for treating EGFR-mutated advanced NSCLC.

Simaravibart (MAD-0004J08), an IgG1κ monoclonal antibody, specifically targets the receptor-binding domain of the SARS-CoV-2 spike (S) glycoprotein [1].

Picankibart (IBI112) is a human recombinant monoclonal antibody targeting IL-23p19, indicated for psoriasis treatment.

Varokibart (TEV-53275) is a human IgG4λ antibody targeting interleukin-5 (IL-5) [1].

Suvemcitug, an IgG1κ antibody, specifically targets vascular endothelial growth factor (VEGF) and is derived from the African hare (Oryctolagus cuniculus) [1].